STAT, July 27, 2023: Prestigious health policy experts and ethicists sent a letter to CMS to urge Medicare to require all Alzheimer’s drug registries to share their de-identified data publicly to allow statistical analyses by CMS and others. NCHR explains why that is important, but Alzheimer’s Association and Beth Israel Hospital don’t plan to comply.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
US Mammogram Update Sparks Concern, Reignites Debates
Medscape, July 9, 2023:Medscape quotes experts disagreeing about what age (40? 50? to start mammograms and we point out that the science suggests different guidelines based on race and risk. Radiologists suggest Black women start at age 35, which would means $$$ for the radiologists but would do more harm than good for most women. USPSTF recommendations raise concerns about costs, accuracy, timing, and ensuring that abnormal mammograms result in biopsies to learn if treatment is needed.
Read More »Alzheimer’s Drug Safety Hinges on Doctors Heeding FDA Warning
Bloomberg Law News, July 12, 2023: NCHR says the FDA black box warnings about brain swelling and bleeding and other cautions about who is most likely to be harmed by Alzheimer’s drug Leqembi will help protect patients with mild cognitive impairment, but only if their doctors pay attention and accurately discuss the risks vs. uncertain benefits with patients and family members.
Read More »No more FDA adcomm votes? Reforms brew as new research highlights decline in meetings
Endpoints News, July 7, 2023: FDA wants to revamp its Advisory Committee meetings but will they make them better or worse? The votes aren’t the problem. We explain that the conflicts of interest of committee members is “outrageous.”
Read More »Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic
STAT News, July 5, 2023: Novo Nordisk gave doctors 450,000 free restaurant meals and snacks in 2022 while promoting drugs like Ozempic for weight loss. One doctor got 183 meals. Some got free trips to Paris or Hawaii. Can those doctors be objective about the risks and benefits of the drugs?
Read More »